Company / Cash & Equivalents
Mettler Toledo Cash & Equivalents History
FY2016-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$69.8M
FY2023
5-year range
$69.8M / $207.8M
FY2019-FY2023
Trend
-25.9%
vs FY2022
Sector context
#124 of 148
Health Care
What the data says
Mettler Toledo's cash & equivalents of $70M is lower than 84% of companies in the Health Care sector (FY2023). Cash & Equivalents has fluctuated over the past 8 years, ranging from $70M in FY2023 to $208M in FY2021.
Based on SEC 10-K filings.
$70M in FY2023 with a 5-year CAGR of -17.1%.
Declined from $208M to $70M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -26.8%
- 5-Year CAGR
- -17.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 16% in Health CareTop 84% of 148This company $69.8M Sector average $1.2B
▼
-94.1% below sector average
Key checks
Key Insights
- 5-year CAGR of -17.1%, indicating a declining trend.
- In FY2023, cash & equivalents decreased 25.9% year-over-year.
- Ranks #124 out of 148 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 3.22 (safe zone, above 2.9 threshold)
- Strong profit margin: 21.2%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $69.8M | -25.9% |
| FY2022 | $94.3M | -54.6% |
| FY2021 | $207.8M | +16.7% |
| FY2020 | $178.1M | +19.8% |
| FY2019 | $148.7M | -16.5% |
| FY2018 | $178.1M | +19.8% |
| FY2017 | $148.7M | -6.3% |
| FY2016 | $158.7M | +60.5% |
As of FY2023 · SEC 10-K · Updated Jun 30, 2026